Literature DB >> 25082626

First reported case of diabetes mellitus type 1 as a possible secondary autoimmune disease following alemtuzumab treatment in MS.

Clas Malmeström1, Bengt A Andersson, Jan Lycke.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25082626     DOI： 10.1007/s00415-014-7448-y

Source DB:  PubMed          Journal:  J Neurol        ISSN： 0340-5354            Impact factor:   4.849


× No keyword cloud information.
  9 in total

Review 1.  Etiology of type 1 diabetes.

Authors:  John A Todd
Journal:  Immunity       Date:  2010-04-23       Impact factor: 31.745

Review 2.  Prediction and pathogenesis in type 1 diabetes.

Authors:  Anette-G Ziegler; Gerald T Nepom
Journal:  Immunity       Date:  2010-04-23       Impact factor: 31.745

3.  Prediction of type 1 diabetes in the general population.

Authors:  Mikael Knip; Sari Korhonen; Petri Kulmala; Riitta Veijola; Antti Reunanen; Olli T Raitakari; Jorma Viikari; Hans K Akerblom
Journal:  Diabetes Care       Date:  2010-06       Impact factor: 19.112

4.  The cation efflux transporter ZnT8 (Slc30A8) is a major autoantigen in human type 1 diabetes.

Authors:  Janet M Wenzlau; Kirstine Juhl; Liping Yu; Ong Moua; Suparna A Sarkar; Peter Gottlieb; Marian Rewers; George S Eisenbarth; Jan Jensen; Howard W Davidson; John C Hutton
Journal:  Proc Natl Acad Sci U S A       Date:  2007-10-17       Impact factor: 11.205

5.  Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial.

Authors:  Jeffrey A Cohen; Alasdair J Coles; Douglas L Arnold; Christian Confavreux; Edward J Fox; Hans-Peter Hartung; Eva Havrdova; Krzysztof W Selmaj; Howard L Weiner; Elizabeth Fisher; Vesna V Brinar; Gavin Giovannoni; Miroslav Stojanovic; Bella I Ertik; Stephen L Lake; David H Margolin; Michael A Panzara; D Alastair S Compston
Journal:  Lancet       Date:  2012-11-01       Impact factor: 79.321

6.  Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial.

Authors:  Alasdair J Coles; Cary L Twyman; Douglas L Arnold; Jeffrey A Cohen; Christian Confavreux; Edward J Fox; Hans-Peter Hartung; Eva Havrdova; Krzysztof W Selmaj; Howard L Weiner; Tamara Miller; Elizabeth Fisher; Rupert Sandbrink; Stephen L Lake; David H Margolin; Pedro Oyuela; Michael A Panzara; D Alastair S Compston
Journal:  Lancet       Date:  2012-11-01       Impact factor: 79.321

Review 7.  Established and emerging biomarkers for the prediction of type 1 diabetes: a systematic review.

Authors:  Renecia A Watkins; Carmella Evans-Molina; Janice S Blum; Linda A DiMeglio
Journal:  Transl Res       Date:  2014-03-04       Impact factor: 7.012

8.  Autoimmune disease after alemtuzumab treatment for multiple sclerosis in a multicenter cohort.

Authors:  M Cossburn; A A Pace; J Jones; R Ali; G Ingram; K Baker; C Hirst; J Zajicek; N Scolding; M Boggild; T Pickersgill; Y Ben-Shlomo; A Coles; N P Robertson
Journal:  Neurology       Date:  2011-07-27       Impact factor: 9.910

Review 9.  Pathogenesis of type 1 diabetes: lessons from natural history studies of high-risk individuals.

Authors:  Natalie Nokoff; Marian Rewers
Journal:  Ann N Y Acad Sci       Date:  2013-01-29       Impact factor: 5.691
  9 in total
  6 in total

1.  Myasthenia gravis following alemtuzumab therapy for multiple sclerosis.

Authors:  Luciana Midaglia; Margarida Gratacòs; Edoardo Caronna; Nuria Raguer; Jaume Sastre-Garriga; Xavier Montalban; Mar Tintoré
Journal:  Neurology       Date:  2018-08-24       Impact factor: 9.910

Review 2.  Alemtuzumab in the treatment of multiple sclerosis: key clinical trial results and considerations for use.

Authors:  Eva Havrdova; Dana Horakova; Ivana Kovarova
Journal:  Ther Adv Neurol Disord       Date:  2015-01       Impact factor: 6.570

3.  Alemtuzumab in the long-term treatment of relapsing-remitting multiple sclerosis: an update on the clinical trial evidence and data from the real world.

Authors:  Tjalf Ziemssen; Katja Thomas
Journal:  Ther Adv Neurol Disord       Date:  2017-08-04       Impact factor: 6.570

Review 4.  Role of Viruses in the Pathogenesis of Multiple Sclerosis.

Authors:  Rachael E Tarlinton; Ekaterina Martynova; Albert A Rizvanov; Svetlana Khaiboullina; Subhash Verma
Journal:  Viruses       Date:  2020-06-13       Impact factor: 5.048

5.  Vitamin D supplementation for the prevention or depletion of side effects of therapy with alemtuzumab in multiple sclerosis.

Authors:  Hans-Klaus Goischke
Journal:  Ther Clin Risk Manag       Date:  2019-07-12       Impact factor: 2.423

6.  Safety of alemtuzumab in a nationwide cohort of Finnish multiple sclerosis patients.

Authors:  Ilkka Rauma; Tiina Mustonen; Juha Matti Seppä; Maritta Ukkonen; Marianne Männikkö; Auli Verkkoniemi-Ahola; Marge Kartau; Jukka T Saarinen; Liisa Luostarinen; Sakari Simula; Mervi Ryytty; Riitta Ahmasalo; Jussi O T Sipilä; Ilkka Pieninkeroinen; Tero Tapiola; Anne M Remes; Hanna Kuusisto
Journal:  J Neurol       Date:  2021-07-13       Impact factor: 4.849
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.